文献速递银屑病与炎症性皮肤病

TNF抑制剂较传统系统药物降低免疫介导炎症性疾病心血管风险:系统综述与荟萃分析

Reducing cardiovascular risk in immune-mediated inflammatory diseases: Tumour necrosis factor inhibitors compared to conventional therapies-A systematic review and meta-analysis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2024-03-03

汇总结果显示TNFi组主要不良心血管事件(MACE)风险显著低于CSNB组(HR=0.74,95%CI 0.58-0.95,p=0.025;IRR=0.77,95%CI 0.67-0.88,p<0.001)。银屑病和银屑病关节炎亚组汇总IRR亦显示MACE风险显著降低(IRR=0.79,95%CI 0.64-0.98)。

要点

  • TNFi较CSNB显著降低IMID患者MACE风险(HR=0.74,95%CI 0.58-0.95)。
  • 银屑病及银屑病关节炎亚组TNFi的MACE风险亦显著降低(IRR=0.79,95%CI 0.64-0.98)。
  • 基于结果,在治疗序列中较早使用TNFi可能有利于IMID患者的心血管风险。

核心结论

  • 在IMID患者中,TNFi较CSNB与MACE风险显著降低相关。
  • 基于结果,在治疗序列中较早使用TNFi可能有利于IMID患者的心血管风险。

研究设计与样本

  • 共纳入56项研究,其中29篇进入荟萃分析,27篇纳入系统综述。
  • 纳入随机对照试验、队列研究和病例对照研究。

主要发现

  • 全部IMID汇总:TNFi组较CSNB组MACE风险显著降低(HR=0.74,95%CI 0.58-0.95,p=0.025)。
  • 全部IMID汇总:TNFi组较CSNB组MACE发生率比显著降低(IRR=0.77,95%CI 0.67-0.88,p<0.001)。
  • 银屑病和银屑病关节炎亚组汇总IRR显示TNFi组MACE风险显著降低(IRR=0.79,95%CI 0.64-0.98)。

临床怎么用

  • 在IMID治疗序列中,较早使用TNFi较传统系统非生物药可能有利于心血管风险。

局限性

  • 多数纳入研究为观察性研究,导致高异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune-mediated inflammatory disease (IMID) patients including psoriasis, inflammatory arthritides and bowel diseases have a higher risk of developing cardiovascular (CV) diseases compared to the general population. The increased CV risk may be promoted by tumour necrosis factor (TNF)-α-mediated immunological processes, which are present both in the pathomechanism of IMIDs and atherosclerosis. Our objective was to comprehensively investigate the effect of TNF inhibitors (TNFi) on CV risk compared with conventional therapies in IMIDs. The systematic literature search was conducted in three databases (MEDLINE, EMBASE, Cochrane Library) on 14 November 2022. Randomized controlled trials, cohort and case-control studies were eligible for inclusion. Outcomes consisted of the incidence of CV events, with major adverse cardiovascular events (MACE) as a main endpoint. A random-effects meta-analysis was performed by pooling fully adjusted multivariate hazard ratios (HR) and incidence rate ratios (IRR) with a 95% confidence interval (CI) comparing TNFis with conventional systemic non-biologicals (CSNBs). Of a total of 8724 search results, 56 studies were included overall, of which 29 articles were eligible for the meta-analysis, and 27 were involved in the systematic review. Including all IMIDs, the TNFi group showed a significantly reduced risk of MACE compared with the CSNB group (HR = 0.74, 95% confidence interval (CI) 0.58-0.95, p = 0.025; IRR = 0.77, 95% CI 0.67-0.88, p < 0.001). Subgroup analysis of Pso, PsA patients by pooling IRRs also confirmed the significantly decreased risk of MACE in TNFi-treated patients compared with CSNB groups (IRR = 0.79, 95% CI 0.64-0.98). The observational nature of most included studies leading to high heterogeneity represents a limitation. Based on the results, TNFis may reduce the risk of CV events compared to CSNBs. Therefore, earlier use of TNFis compared to conventional systemic agents in the therapeutic sequence may benefit CV risk in IMID patients.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Galajda NÁ, Meznerics FA, Mátrai P, et al. Reducing cardiovascular risk in immune-mediated inflammatory diseases: Tumour necrosis factor inhibitors compared to conventional therapies-A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2024. PMID: 38433519. doi:10.1111/jdv.19900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。